PARIS--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes. Sanofi will invest about $325 ...

I want to mention as well that with the new tax laws in France ... specific here or is it a way for Sanofi to maybe be more ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight ...

Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements.